These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

443 related items for PubMed ID: 7949179

  • 1. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia.
    Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, Kita K, Hiraoka A, Masaoka T, Nasu K.
    Blood; 1994 Nov 01; 84(9):3071-9. PubMed ID: 7949179
    [Abstract] [Full Text] [Related]

  • 2. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels.
    Inoue K, Ogawa H, Yamagami T, Soma T, Tani Y, Tatekawa T, Oji Y, Tamaki H, Kyo T, Dohy H, Hiraoka A, Masaoka T, Kishimoto T, Sugiyama H.
    Blood; 1996 Sep 15; 88(6):2267-78. PubMed ID: 8822948
    [Abstract] [Full Text] [Related]

  • 3. [WT 1 and leukemia].
    Inoue K, Sugiyama H.
    Rinsho Ketsueki; 1995 Jun 15; 36(6):552-8. PubMed ID: 7643450
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Detection of minimal residual disease in a patient with acute promyelocytic leukemia by RT-PCR: necessity of chemotherapy following ATRA therapy.
    Sun T, Takatsuki H, Yamashita S, Yufu Y, Umemura T, Nishimura J, Nawata H.
    Fukuoka Igaku Zasshi; 1994 Feb 15; 85(2):52-6. PubMed ID: 8144129
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: evaluation of PML-RAR alpha and RAR alpha-PML assessment in patients who ultimately relapse.
    Grimwade D, Howe K, Langabeer S, Burnett A, Goldstone A, Solomon E.
    Leukemia; 1996 Jan 15; 10(1):61-6. PubMed ID: 8558940
    [Abstract] [Full Text] [Related]

  • 14. Quantification of WT1 mRNA by competitive NASBA in AML patients.
    Fukahori S.
    Kurume Med J; 2001 Jan 15; 48(2):129-34. PubMed ID: 11501493
    [Abstract] [Full Text] [Related]

  • 15. Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study.
    Willasch AM, Gruhn B, Coliva T, Kalinova M, Schneider G, Kreyenberg H, Steinbach D, Weber G, Hollink IH, Zwaan CM, Biondi A, van der Velden VH, Reinhardt D, Cazzaniga G, Bader P, Trka J, European Study Group on WT1 Expression in Childhood AML.
    Leukemia; 2009 Aug 15; 23(8):1472-9. PubMed ID: 19322206
    [Abstract] [Full Text] [Related]

  • 16. [Genetic diagnosis of leukemia: diagnosis of relapse and complete remission, and prediction of leukemia onset].
    Sugiyama H.
    Rinsho Byori; 2000 Feb 15; 48(2):155-61. PubMed ID: 10804819
    [Abstract] [Full Text] [Related]

  • 17. [Clinical significance of quantitation of WT1 gene expression for minimal residual disease monitoring of acute myelogenous leukemia].
    Kim HR, Shin JH, Lee JN, Lee EY.
    Korean J Lab Med; 2007 Oct 15; 27(5):305-12. PubMed ID: 18094593
    [Abstract] [Full Text] [Related]

  • 18. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.
    Boublikova L, Kalinova M, Ryan J, Quinn F, O'Marcaigh A, Smith O, Browne P, Stary J, McCann SR, Trka J, Lawler M.
    Leukemia; 2006 Feb 15; 20(2):254-63. PubMed ID: 16341043
    [Abstract] [Full Text] [Related]

  • 19. Wilms tumor gene (WT1) as a new marker for the detection of minimal residual disease in leukemia.
    Sugiyama H.
    Leuk Lymphoma; 1998 Jun 15; 30(1-2):55-61. PubMed ID: 9669676
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.